Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Nova Mentis Life Science Corp (NOVA.CN)

Nova Mentis Life Science Corp (NOVA.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 1,472
  • Shares Outstanding, K 147,169
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,466 K
  • 60-Month Beta -2.37
  • Price/Sales 51.40
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade NOVA.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings $0.00 on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0100 unch
on 05/10/24
0.0200 -50.00%
on 04/25/24
-0.0050 (-33.33%)
since 04/10/24
3-Month
0.0100 unch
on 05/10/24
0.0250 -60.00%
on 02/20/24
-0.0050 (-33.33%)
since 02/09/24
52-Week
0.0100 unch
on 05/10/24
0.0550 -81.82%
on 05/26/23
-0.0400 (-80.00%)
since 05/10/23

Most Recent Stories

More News
Nova Mentis Announces Change of Directors

Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company") announces the appointment of Steve Loutskou...

NMLSF : 0.0112 (+7.69%)
NOVA.CN : 0.0100 (unch)
Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group

Vancouver, British Columbia--(Newsfile Corp. - November 3, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader...

NMLSF : 0.0112 (+7.69%)
NOVA.CN : 0.0100 (unch)
Nova Mentis Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome

Vancouver, British Columbia--(Newsfile Corp. - August 30, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader...

NMLSF : 0.0112 (+7.69%)
NOVA.CN : 0.0100 (unch)
Nova Mentis to Enter mRNA AI Diagnostics Business

Vancouver, British Columbia--(Newsfile Corp. - April 26, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader...

NMLSF : 0.0112 (+7.69%)
NOVA.CN : 0.0100 (unch)
Nova Mentis Begins Recruitment in First-of-its-Kind Health Canada Psilocybin Trial

Vancouver, British Columbia--(Newsfile Corp. - April 18, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader...

NMLSF : 0.0112 (+7.69%)
NOVA.CN : 0.0100 (unch)
Nova Mentis Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial

Vancouver, British Columbia--(Newsfile Corp. - April 11, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader...

NMLSF : 0.0112 (+7.69%)
NOVA.CN : 0.0100 (unch)
Nova Mentis Provides Corporate Update and 2023 Outlook

Vancouver, British Columbia--(Newsfile Corp. - April 5, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader...

NMLSF : 0.0112 (+7.69%)
NOVA.CN : 0.0100 (unch)
Novel Therapeutic Solutions are Needed as Autism Rates Increase

Vancouver, British Columbia--(Newsfile Corp. - March 29, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader...

NMLSF : 0.0112 (+7.69%)
NOVA.CN : 0.0100 (unch)
Nova Mentis Granted Health Canada Section 56 Exemption to Begin Psilocybin Clinical Trial

Vancouver, British Columbia--(Newsfile Corp. - February 14, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader...

NMLSF : 0.0112 (+7.69%)
NOVA.CN : 0.0100 (unch)
Nova Mentis Appoints Derek Ivany as Executive Chairman

Vancouver, British Columbia--(Newsfile Corp. - January 18, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader...

NMLSF : 0.0112 (+7.69%)
NOVA.CN : 0.0100 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company's goal is to diagnose and treat debilitating...

See More

Key Turning Points

3rd Resistance Point 0.0100
2nd Resistance Point 0.0100
1st Resistance Point 0.0100
Last Price 0.0100
1st Support Level 0.0100
2nd Support Level 0.0100
3rd Support Level 0.0100

See More

52-Week High 0.0550
Fibonacci 61.8% 0.0378
Fibonacci 50% 0.0325
Fibonacci 38.2% 0.0272
Last Price 0.0100
52-Week Low 0.0100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar